Recently, the 2026 (9th) China Economic Conference successfully concluded in Hong Kong. Zhuhai Langjian Biotechnology Co., Ltd., with its hardcore strengths in independent R&D of underlying technologies, breakthroughs in key processes, and innovation in industrialization implementation, stood out among numerous participating enterprises and won the honor of “2026 (Industry) Technology Innovation Enterprise,” ranking among China’s highly innovative biotechnology enterprises.

With the theme “New Quality Leadership, Resilient Growth,” this year’s conference brought together many guests from the political, business, academic, and media sectors to engage in in-depth exchanges around core topics such as brand building, digital and intelligent transformation, and resilient corporate growth, injecting new momentum into China’s high-quality economic development. Langjian Biotechnology’s award this time is not only recognition by the organizing committee of the company’s technological strength and industrial contribution, but also confirms that the synthetic biology intelligent manufacturing track is becoming an indispensable force in China’s new quality productive forces landscape.

Human milk oligosaccharides (HMOs), as core ingredients in maternal and infant nutrition and functional health, represent a highly representative challenging track in synthetic biology intelligent manufacturing. This category has complex synthesis pathways and extremely high difficulty in strain development and purification, and has long been monopolized overseas, making it a “bottleneck” track constraining the independent upgrading of China’s broader health industry. The industry generally faces pain points such as high R&D investment, insufficient mass-production stability, and dependence on imported core processes, and for a long time China lacked local enterprises with full-chain independent R&D capabilities.

Zhuhai Langjian Biotechnology has always adhered to technological innovation and, relying on synthetic biology, built a full-chain self-developed system covering strain design, enzymatic catalysis, intelligent fermentation, and high-precision purification. With intelligent screening, digital quality control, and novel purification technologies, the company has solved the challenges of purity, capacity, and cost in HMO mass production, achieving standardized, high-quality mass production of multiple core HMOs including 2'-FL and LNnT, and realizing independent and controllable core technologies, processes, and product supply.

Compared with homogenized industry development, the innovation value of Zhuhai Langjian Biotechnology is reflected not only in product iteration and process optimization, but also in building a replicable and implementable localized technology paradigm for China’s high-end nutritional ingredient track, filling the gap in domestic high-end HMO industrialization innovation.

Honors reflect past achievements, while technology defines the future. Standing at a new starting point for industrial upgrading in 2026, Zhuhai Langjian Biotechnology will remain anchored to its core HMO business and adhere to a deep-cultivation strategy in its niche track. In the future, the company will continue to focus on four core technology directions: strain optimization, biocatalysis upgrading, purification process iteration, and mass-production system improvement. It will continuously refine product quality, enrich its product matrix, and enhance industrialization capabilities. With solid technological iteration, stable production strength, and stringent quality standards, it will continue to deliver highly compliant, highly safe, and high-quality domestic HMO ingredient solutions, and continue to boost the localization, specialization, and refinement upgrading of the maternal and infant nutrition and functional health industry.